Recent Advances in nccRCC Classification and Therapeutic Approaches

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Non-clear cell renal cell carcinoma (nccRCC) is a diverse group of kidney cancers.
• Current treatments for advanced nccRCC are often based on clear cell renal cell carcinoma (ccRCC) approaches and are suboptimal.
• The 2022 WHO classification recognizes molecularly defined entities in nccRCC.

Purpose of the Study:

• To review how multi-omics approaches can address the heterogeneity of nccRCC.
• To highlight the identification of novel nccRCC subtypes based on molecular characteristics.
• To establish a framework for precision oncology in nccRCC management.

Main Methods:

• Review of multi-omics data (genomics, transcriptomics, epigenomics, etc.) for nccRCC.
• Analysis of molecular data to identify distinct nccRCC subtypes.
• Correlation of molecular subtypes with immune microenvironment, metabolic profiles, and genomic instability.

Main Results:

• Multi-omics approaches enable molecular stratification of nccRCC beyond traditional pathology.
• Novel nccRCC subtypes are identified, characterized by distinct biological features.
• These subtypes show unique immune microenvironment, metabolic, and genomic instability patterns.

Conclusions:

• Molecular reclassification of nccRCC using multi-omics is essential for understanding its heterogeneity.
• This approach provides a foundation for precision oncology, guiding patient selection for targeted and immunomodulatory therapies.
• Advancements in multi-omics subtyping are crucial for biomarker-driven therapeutic development in nccRCC.